85 results
6-K
EX-99.1
GLPG
Galapagos NV
3 Oct 22
Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies
6:02pm
as Jyseleca (200mg and 100mg tablets) in the European Union (incl. Norway), Great Britain, and Japan for the treatment of adults with moderately … (DMARDs). Filgotinib is also marketed as Jyseleca (200mg tablets) in the European Union (incl. Norway), Great Britain, and Japan for the treatment of adult
6-K
EX-99.1
GLPG
Galapagos NV
17 Nov 21
Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis
6:00am
EXHIBIT 99.1
Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis
Mechelen, Belgium; 15 November 2021 … patients. Our focus now is on making this treatment available as rapidly as possible to physicians and UC patients across the European Union,” said Onno
6-K
EX-99.1
GLPG
Galapagos NV
6 Oct 22
Current report (foreign)
5:11pm
as well. (Feagan et al., Lancet 2021; 397: 2372–84)
About filgotinib
Filgotinib is marketed as Jyseleca (200mg and 100mg tablets) in the European Union … ) in the European Union (incl. Norway), Great Britain, and Japan for the treatment of adult patients with moderately to severely active ulcerative
6-K
EX-99.1
GLPG
Galapagos NV
14 Nov 22
Current report (foreign)
6:05am
Characteristics (SmPC) will be updated.
About filgotinib
Filgotinib is marketed as Jyseleca in the European Union (incl. Norway), Great Britain, and Japan … or more disease modifying anti-rheumatic drugs (DMARDs). Filgotinib is also marketed as Jyseleca in the European Union (incl. Norway), Great Britain
6-K
EX-99.1
GLPG
Galapagos NV
3 Nov 20
Current report (foreign)
6:00am
more than 2 million people in the European Union alone. Symptoms tend to present intermittently, and so patients usually experience flare-ups … 27 member states of the European Union, as well as Norway, Iceland and Liechtenstein. Filgotinib is already licensed in the European Union
6-K
EX-99.1
nrp3w6e25lr7c89v
9 Nov 22
Current report (foreign)
4:05pm
6-K
EX-99.1
qzbndn v2bqys4ii7rc
28 Mar 22
Jyseleca® approved in Japan for ulcerative colitis
1:50pm
6-K
EX-99.1
jphrhqzh7 mwd593w
19 Jan 22
Jyseleca®▼ (Filgotinib) Licensed for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis In Great Britain
11:37am
6-K
EX-99.1
ixwhh 8flq6dd
2 Nov 23
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
7:15am
6-K
EX-99.1
fepjnbp4wdi9b
6 Oct 21
Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease
6:00am
6-K
EX-99.1
vwv 2qu2iy8zwj
6 Oct 21
Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress
6:00am
6-K
EX-99.1
gjwgh04p 0kqnp
7 Feb 22
Current report (foreign)
2:40pm
6-K
EX-99.1
fihhfd2hzpswy
31 May 22
Current report (foreign)
1:39pm
6-K
EX-99.1
lpgc2mnllbozkb0ok2k3
19 Aug 22
Galapagos receives transparency notification from FMR LLC
8:43am
6-K
EX-99.1
yqlzwxvw
24 Aug 22
Galapagos to present at upcoming investor conferences
4:48pm
6-K
EX-99.1
khv etmoo6fpt2
9 Aug 22
Galapagos receives transparency notification from FMR LLC
6:20am
6-K
EX-99.1
x400eb 4mysl2zays1xk
30 Aug 22
Galapagos receives transparency notification from FMR LLC
6:00am
6-K
EX-99.1
zr7og18
17 Oct 22
Galapagos to host its R&D Update 2022 in New York on 4 November 2022
6:05am
6-K
EX-99.1
0wds7eqzh9gq
27 Sep 22
Current report (foreign)
5:03pm